The analysis of a de novo 8q12.2-q21.2 deletion led to the identification of a proposed previously undescribed contiguous gene syndrome consisting of Branchio-Oto-Renal (BOR) syndrome, Duane syndrome, hydrocephalus and trapeze aplasia. This is the first reported localization of the genes responsible for Duane syndrome and this dominant form of hydrocephalus. In contrast, we report a new localization for the gene responsible for BOR syndrome which is more telomeric to an initial placement. Linkage analysis of affected families consistently mapped the gene responsible for BOR and Branchio-Oto (BO) syndromes to within the deletion. Using new algorithms, a YAC contig was constructed and used to localize the breakpoint of another chromosomal rearrangement associated with BO syndrome to a 500 kb interval within the deletion. The 8q12.2-q21.2 deletion suggests that reduced dosage of the relevant genes is sufficient to cause Duane syndrome, BOR syndrome and this dominant form of hydrocephalus.

Download full-text PDF

Source
http://dx.doi.org/10.1093/hmg/3.10.1859DOI Listing

Publication Analysis

Top Keywords

bor syndrome
16
duane syndrome
16
syndrome dominant
12
dominant form
12
form hydrocephalus
12
syndrome
11
contiguous gene
8
gene syndrome
8
branchio-oto-renal bor
8
syndrome duane
8

Similar Publications

A 17 year old male patient presented with bilateral preauricular sinus, right sided second branchial cleft sinus and bilateral hearing deficit. He has previous history of right congenital cataract surgery and right dacryocystorhinostomy at the age of 8 year. He was operated for branchial sinus.

View Article and Find Full Text PDF
Article Synopsis
  • Syndromic hearing loss (SHL) involves diverse genetic causes, with over 400 types identified, primarily following an autosomal dominant inheritance pattern.
  • A study analyzed 14 patients (ages 5-78 months) with various syndromes associated with SHL, discovering ten new genetic variants and confirming cases of well-known syndromes like Waardenburg and CHARGE.
  • Results suggest that combining neonatal hearing screenings with whole exome sequencing can effectively diagnose SHL early, highlighting the need for thorough monitoring of patients due to the complexity and variability of SHL symptoms.
View Article and Find Full Text PDF
Article Synopsis
  • Branchio-oto-renal (BOR) spectrum disorders involve genetic changes in the EYA1 gene, making prenatal detection challenging due to varied symptoms.
  • A new pathogenic variant in the EYA1 gene was identified during a study of pregnant women who underwent fetal whole-exome sequencing, alongside a review of previous cases.
  • The findings highlight that subtle manifestations complicate prenatal ultrasounds, with particular emphasis on amniotic fluid and cardiac issues, and suggest that certain genetic markers could enhance early diagnosis of these disorders.
View Article and Find Full Text PDF

Incoherent collective cell chemotaxis underlies organ dysmorphia in a model of branchio-oto-renal syndrome.

MicroPubl Biol

September 2024

Department of Neurophysiology and Developmental Neurobiology,, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Juriquilla, México.

Article Synopsis
  • Mutations in the gene responsible for branchio-oto-renal syndrome (BOR) cause multi-organ malformations in humans and similar effects in animal models.
  • Researchers studied the zebrafish posterior lateral-line primordium to investigate the role of the Eya1 gene in organ development.
  • Their findings revealed that the loss of Eya1 reduces specific chemokine receptor expression, disrupting cell movement and leading to abnormal formation of the lateral line, which suggests that issues with cell movement contribute to organ malformations in BOR.
View Article and Find Full Text PDF

Introduction: Vitamin-K antagonists (VKA) are considered the first-line anticoagulants for thrombotic antiphospholipid syndrome (TAPS), particularly with triple positivity or arterial events. However, thrombotic recurrence remains high despite anticoagulation and other clinical issues may arise. Long-term parenteral anticoagulants may therefore be considered, however little is known about the viability of fondaparinux in this setting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!